Targeting TGFb In Osteogenesis Imperfecta

靶向 TGFb 治疗成骨不全症

基本信息

  • 批准号:
    10736736
  • 负责人:
  • 金额:
    $ 62.59万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2023
  • 资助国家:
    美国
  • 起止时间:
    2023-09-07 至 2028-06-30
  • 项目状态:
    未结题

项目摘要

PROJECT SUMMARY Osteogenesis Imperfecta (OI) is a group of heterogeneous brittle bone disorders. Over 95% of patients harbor dominantly inherited structural mutations in the type I procollagen genes (COL1A1 and COL1A2) or recessively inherited mutations in the protein complexes important in type I collagen post-translational assembly and hydroxylation. Currently, there are no FDA-approved treatments for OI. While off-label use of anti-resorptive bisphosphonates has become a de facto standard of care especially in children with OI, their clinical impact on fracture incidence, mild OI type I (> 50% of patients), and adult, severe OI with lower bone formation is unclear. This highlights the critical need of therapeutic innovations for OI. Taking anabolic approaches, we have shown in adult OI that teriparatide (PTH 1-34) increases lumbar spine BMD in mild OI type I, but surprisingly, had no significant effect in severe OI, suggesting the possibility of combinatorial therapy to overcome PTH insensitivity. We and others have shown that collagen over-modification and altered cross-linking lead to abnormal mineralization and altered extracellular matrix (ECM)-to-cell signaling, in particular, excessive TGFβ signaling in OI in mice (Col1a2G610C/+ and Crtap-/-). Pan-anti-TGFβ treatment rescued the skeletal phenotype in these mice. In primary fetal rat osteoblasts, TGFβ downregulates PTH 1 receptor, which led us to hypothesize that TGFβ signaling contributes to PTH insensitivity in moderate and severe OI (Aim 1). On the severe end of the spectrum, others have shown that Col1a1Jrt/+ mice also have increased TGFβ; however, they did not respond to anti-TGFβ at doses that were effective in the moderate OI models. In our phase 1 anti-TGFβ clinical trial, increase lumbar spine BMD was observed in moderate but not severe OI participants after a single dose. Our unpublished preliminary data also showed increase TGFβ in our mild Col1a1+/- OI mice. We therefore hypothesize a wide dose/frequency range requirement for anti-TGFβ among different OI severities and a bone-targeted antibody can improve efficacy and safety across all types (Aim 2). TGFβ is also critical in fracture healing. We previously found delayed fracture healing with reduced callus size in Col1a2G610C/+ and Crtap-/- mice and anti-TGFβ further reduced this. This observation underscores the importance for studying the effects of anti-TGFβ in the course of fracture repair for future clinical management (Aim 3). Finally, understanding the mechanism of TGFβ excess in OI bone could potentially lead to new therapeutic targets. One hypothesis for this is decreased interaction between abnormal collagen and small leucine rich proteoglycans, like Decorin, which sequester mature TGFβ (Aim 4). Our overall goal is to answer the questions and unmet needs around targeting TGFβ in OI. Aim 1. Is PTH insensitivity in mice and patients with OI type III/IV due to excessive TGFβ? Aim 2. Develop a bone- targeted anti-TGFβ antibody and determine the dose range for mild, moderate, and severe OI. Aim 3. Assess the short and long-term effects of anti-TGFβ treatment in OI fracture repair. Aim 4. Determine the genetic requirement of Decorin in modulating excessive TGFβ in OI.
项目摘要 成骨不全症是一组异质性脆性骨疾病。超过95%的患者 I型前胶原基因(COL 1A 1和COL 1A 2)中存在显性遗传结构突变,或 在I型胶原蛋白翻译后组装中重要的蛋白复合物中的reckonin遗传突变 和羟基化。目前,没有FDA批准的OI治疗方法。虽然抗骨吸收剂的标签外使用 双膦酸盐已成为事实上的标准治疗,特别是在患有OI的儿童中,其临床影响 骨折发生率、轻度I型OI(> 50%的患者)和成人重度OI伴下部骨形成尚不清楚。 这突出了对OI的治疗创新的迫切需要。采用合成代谢方法,我们已经证明 在成人OI中,特立哌酮(PTH 1-34)增加轻度OI I型腰椎BMD,但令人惊讶的是, 在严重的OI中具有显著的效果,提示了克服PTH不敏感性的组合疗法的可能性。 我们和其他人已经表明,胶原蛋白的过度修饰和改变的交联导致异常的 矿化和改变的细胞外基质(ECM)-细胞信号传导,特别是过度的TGFβ信号传导, 小鼠OI(Col 1a 2G 610 C/+和Crtap-/-)。泛抗TGFβ治疗挽救了这些小鼠的骨骼表型。 在原代胎鼠成骨细胞中,TGFβ下调PTH 1受体,这使我们假设TGFβ 在中度和重度OI中,信号传导导致PTH不敏感(Aim 1)。在极端情况下, 其他研究表明,Col 1a 1 Jrt/+小鼠也有TGFβ增加;然而,它们对抗TGF β没有反应, 在中度OI模型中有效的剂量。在我们的1期抗TGF β临床试验中, 单次给药后,在中度但非重度OI参与者中观察到脊柱BMD。我们未发表 初步数据还显示在我们的轻度Col 1a 1 +/- OI小鼠中TGFβ增加。因此,我们假设 不同OI严重程度和骨靶向抗体中抗TGF β的剂量/频率范围要求 可以提高所有类型的疗效和安全性(目标2)。TGFβ在骨折愈合中也至关重要。我们之前 发现Col 1a 2G 610 C/+和Crtap-/-小鼠骨折愈合延迟,骨痂尺寸减小,抗TGF β进一步 减少了这个。这一观察结果强调了研究抗TGF β在治疗过程中的作用的重要性。 骨折修复的未来临床管理(目标3)。最后,了解TGFβ过量的机制, OI骨可能导致新的治疗靶点。其中一个假设是减少互动 异常胶原蛋白和富含亮氨酸的小蛋白聚糖之间的关系,如核心蛋白聚糖,它可以隔离成熟的TGFβ (Aim 4).我们的总体目标是回答有关在OI中靶向TGFβ的问题和未满足的需求。目标1.是 过量TGFβ导致小鼠和III/IV型OI患者PTH不敏感?目标二。把骨头- 靶向抗TGF β抗体,并确定轻度、中度和重度OI的剂量范围。目标3. 评估抗TGF β治疗在OI骨折修复中的短期和长期效果。目标4。确定 核心蛋白聚糖在调节OI中过量TGFβ中的遗传需求。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Brendan Lee其他文献

Brendan Lee的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Brendan Lee', 18)}}的其他基金

Regulation of Skeletal progenitor cells in Osteogenesis Imperfecta
成骨不全中骨骼祖细胞的调节
  • 批准号:
    10528208
  • 财政年份:
    2022
  • 资助金额:
    $ 62.59万
  • 项目类别:
Regulation of Skeletal progenitor cells in Osteogenesis Imperfecta
成骨不全中骨骼祖细胞的调节
  • 批准号:
    10665057
  • 财政年份:
    2022
  • 资助金额:
    $ 62.59万
  • 项目类别:
ALL OF US EVENINGS WITH GENETICS RESEARCH EDUCATION PROGRAM
我们所有的晚间遗传学研究教育计划
  • 批准号:
    10307410
  • 财政年份:
    2021
  • 资助金额:
    $ 62.59万
  • 项目类别:
ALL OF US EVENINGS WITH GENETICS RESEARCH EDUCATION PROGRAM
我们所有的晚间遗传学研究教育计划
  • 批准号:
    10663584
  • 财政年份:
    2021
  • 资助金额:
    $ 62.59万
  • 项目类别:
WNT1 Function in Stem Cells in Osteogenesis Imperfecta and Craniofacial-Skeletal Tissues
WNT1 在成骨不全和颅面骨骼组织干细胞中的功能
  • 批准号:
    10316864
  • 财政年份:
    2021
  • 资助金额:
    $ 62.59万
  • 项目类别:
ALL OF US EVENINGS WITH GENETICS RESEARCH EDUCATION PROGRAM
我们所有的晚间遗传学研究教育计划
  • 批准号:
    10804507
  • 财政年份:
    2021
  • 资助金额:
    $ 62.59万
  • 项目类别:
WNT1 Function in Stem Cells in Osteogenesis Imperfecta and Craniofacial-Skeletal Tissues
WNT1 在成骨不全和颅面骨骼组织干细胞中的功能
  • 批准号:
    10684863
  • 财政年份:
    2021
  • 资助金额:
    $ 62.59万
  • 项目类别:
Nitric Oxide and Bone Homeostasis in Patients with Argininosuccinate Lyase Deficiency
精氨基琥珀酸裂解酶缺乏症患者的一氧化氮和骨稳态
  • 批准号:
    9329788
  • 财政年份:
    2017
  • 资助金额:
    $ 62.59万
  • 项目类别:
Nitric Oxide and Bone Homeostasis in Patients with Argininosuccinate Lyase Deficiency
精氨基琥珀酸裂解酶缺乏症患者的一氧化氮和骨稳态
  • 批准号:
    9896758
  • 财政年份:
    2017
  • 资助金额:
    $ 62.59万
  • 项目类别:
BRITTLE BONE DISORDERS CONSORTIUM OF THE RARE DISEASE CLINICAL RESEARCH NETWORK
罕见疾病临床研究网络脆性骨疾病联盟
  • 批准号:
    10392597
  • 财政年份:
    2014
  • 资助金额:
    $ 62.59万
  • 项目类别:

相似海外基金

RII Track-4:NSF: From the Ground Up to the Air Above Coastal Dunes: How Groundwater and Evaporation Affect the Mechanism of Wind Erosion
RII Track-4:NSF:从地面到沿海沙丘上方的空气:地下水和蒸发如何影响风蚀机制
  • 批准号:
    2327346
  • 财政年份:
    2024
  • 资助金额:
    $ 62.59万
  • 项目类别:
    Standard Grant
BRC-BIO: Establishing Astrangia poculata as a study system to understand how multi-partner symbiotic interactions affect pathogen response in cnidarians
BRC-BIO:建立 Astrangia poculata 作为研究系统,以了解多伙伴共生相互作用如何影响刺胞动物的病原体反应
  • 批准号:
    2312555
  • 财政年份:
    2024
  • 资助金额:
    $ 62.59万
  • 项目类别:
    Standard Grant
How Does Particle Material Properties Insoluble and Partially Soluble Affect Sensory Perception Of Fat based Products
不溶性和部分可溶的颗粒材料特性如何影响脂肪基产品的感官知觉
  • 批准号:
    BB/Z514391/1
  • 财政年份:
    2024
  • 资助金额:
    $ 62.59万
  • 项目类别:
    Training Grant
Graduating in Austerity: Do Welfare Cuts Affect the Career Path of University Students?
紧缩毕业:福利削减会影响大学生的职业道路吗?
  • 批准号:
    ES/Z502595/1
  • 财政年份:
    2024
  • 资助金额:
    $ 62.59万
  • 项目类别:
    Fellowship
Insecure lives and the policy disconnect: How multiple insecurities affect Levelling Up and what joined-up policy can do to help
不安全的生活和政策脱节:多种不安全因素如何影响升级以及联合政策可以提供哪些帮助
  • 批准号:
    ES/Z000149/1
  • 财政年份:
    2024
  • 资助金额:
    $ 62.59万
  • 项目类别:
    Research Grant
感性個人差指標 Affect-X の構築とビスポークAIサービスの基盤確立
建立个人敏感度指数 Affect-X 并为定制人工智能服务奠定基础
  • 批准号:
    23K24936
  • 财政年份:
    2024
  • 资助金额:
    $ 62.59万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
How does metal binding affect the function of proteins targeted by a devastating pathogen of cereal crops?
金属结合如何影响谷类作物毁灭性病原体靶向的蛋白质的功能?
  • 批准号:
    2901648
  • 财政年份:
    2024
  • 资助金额:
    $ 62.59万
  • 项目类别:
    Studentship
ERI: Developing a Trust-supporting Design Framework with Affect for Human-AI Collaboration
ERI:开发一个支持信任的设计框架,影响人类与人工智能的协作
  • 批准号:
    2301846
  • 财政年份:
    2023
  • 资助金额:
    $ 62.59万
  • 项目类别:
    Standard Grant
Investigating how double-negative T cells affect anti-leukemic and GvHD-inducing activities of conventional T cells
研究双阴性 T 细胞如何影响传统 T 细胞的抗白血病和 GvHD 诱导活性
  • 批准号:
    488039
  • 财政年份:
    2023
  • 资助金额:
    $ 62.59万
  • 项目类别:
    Operating Grants
How motor impairments due to neurodegenerative diseases affect masticatory movements
神经退行性疾病引起的运动障碍如何影响咀嚼运动
  • 批准号:
    23K16076
  • 财政年份:
    2023
  • 资助金额:
    $ 62.59万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了